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The human immunodeficiency virus type 1 (HIV-1) Vpu accessory protein is a transmembrane protein that
down regulates CD4 expression and promotes the release of new virions. We screened a human leukocyte-
specific yeast two-hybrid expression library to discover novel Vpu-interacting cellular proteins. The major
histocompatibility complex class II (MHC II) invariant chain, also called Ii or CD74, was found to be one such
protein. We show direct binding of Vpu and CD74 by using a yeast two-hybrid assay and coimmunoprecipi-
tation from HIV-1-infected cells. The cytoplasmic region of Vpu was found to interact with the 30-amino-acid
cytoplasmic tail of CD74. Human monocytic U937 cells infected with wild-type or Vpu-defective HIV-1 and
transfected cells showed that Vpu down modulated the surface expression of mature MHC II molecules. The
reduction in cell surface mature MHC II molecules correlated with decreased antigen presentation to T cells
in culture. Thus, the Vpu protein also contributes to viral persistence by attenuating immune responses during
HIV infection. This report further exemplifies the rich diversity and redundancy shown by HIV in immune
evasion.
Human immunodeficiency virus type 1 (HIV-1) is a complex
retrovirus and is the causative agent of AIDS (14). Besides
coding for the typical retroviral Gag, Pol, and Env proteins, the
HIV-1 genome also encodes the regulatory Tat and Rev pro-
teins and the accessory Vif, Vpr, Vpu, and Nef proteins (14).
The accessory proteins are required for establishment and
persistence of infection in the host but are dispensable for HIV
replication in vitro (14). The vpu gene is found exclusively in
HIV-1 and some HIV-1-related simian immunodeficiency vi-
rus (SIV) isolates, such as SIVcpz, SIVgsn, and SIVmon, but
not in HIV-2 or the majority of SIV isolates (10–12, 23). Two
main functions have been assigned to the Vpu protein; they are
enhancement of virus release from infected cells (26, 41, 47,
50) and degradation of the HIV receptor CD4 protein in the
endoplasmic reticulum (ER) (53). Whether Vpu is a virulence
factor remains to be established, but compared to HIV-1,
closely related retroviruses, such as HIV-2 and SIV, that lack
expression of a fully functional Vpu protein also cause less
severe disease outcomes. Vpu-defective HIV-1 mutants repli-
cate poorly in CD4 T cells and macrophages, and recent
studies with macaques have demonstrated that Vpu-defective
simian-human immunodeficiency virus (SHIV) strains are at-
tenuated in vivo.
The Vpu protein is an 81-amino-acid (81-aa) type I integral
membrane protein with two major domains, namely, an N-
terminal transmembrane (TM) domain that anchors it in the
cellular membrane and appears to form a cation channel and
a carboxyl-terminal cytoplasmic domain that contains two am-
phipathic alpha helices (10, 47). Between these helices are
positioned two serine residues (S52 and S56) that are phos-
phorylated by cellular casein kinase II (42). The ability of Vpu
to induce CD4 degradation depends on these phosphoserines
through binding of beta-transducin repeat-containing protein
(TrCP) and the formation of an E3 ubiquitin ligase complex
at the ER (2, 31). This association polyubiquitinates CD4 at its
cytoplasmic tail and marks it for proteasomal degradation (16,
40). TrCP is part of a complex that also regulates degradation
of various cellular substrates, including -catenin and inhibitor
of kappa B (IB); its stable association with Vpu affects the
Wnt and nuclear factor kappa B (NF-B) signaling pathways
(1, 5). In HIV-infected cells, Vpu is synthesized from a bicis-
tronic mRNA that also codes for the viral envelope (Env)
protein gp160. While these two proteins are synthesized at
similar rates, unlike the Env protein, which is packaged into
virions and exported from the cell, Vpu remains largely cell
associated and accumulates over time in infected cells (6).
Another function of Vpu is to enhance viral particle release
from the cell (26), and this depends largely on the TM domain
of Vpu, which also shows ion channel activity (13). Early stud-
ies showed that expression of Vpu could enhance the release of
diverse retroviral particles from human cells, irrespective of
whether those retroviruses normally carry a Vpu protein (17).
More recent studies suggest that Vpu, as well as the Vpu-like
activity of HIV-2 envelope proteins, acts by overcoming a
novel species-specific host restriction to HIV release (51). The
expression of Vpu in trans rescued Vpu-defective HIV-1 re-
lease to levels similar to those of the wild-type virus. The
pericentriolar recycling endosome has been shown to be im-
portant for Vpu-mediated particle release and was proposed to
be a potential site for interaction between Vpu and the host
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restriction factor (52). The Vpu protein prevents accumulation
of HIV-1 and murine leukemia virus Gag in endosomal com-
partments and instead constrains Gag accumulation to the
plasma membrane (36). This is likely to positively influence the
assembly and release of newly synthesized virions.
Viral proteins are known to perform multiple functions in
infected cells by interacting with a variety of cellular proteins.
In this study, we used a yeast two-hybrid screen to identify
novel host proteins that might bind Vpu. One such protein, the
major histocompatibility complex class II (MHC II) invariant
chain (Ii), also called CD74, was further characterized for its
interaction with HIV-1 Vpu and for functional effects on MHC
II following HIV infection. Our results support a role for the
Vpu protein in attenuating immune responses and thus con-
tributing to viral persistence.
MATERIALS AND METHODS
Cells and viruses. The human monocytic cell line U937 was maintained in
RPMI containing 10% fetal bovine serum in a 5% CO2 environment. HIV-1
stocks were generated by electroporation of HeLa cells with the HIV-1 infectious
molecular clones pNL4-3 (wild type) and pNL4-3U35 (vpu deleted), obtained
from the NIH AIDS Reagent and Reference Program. The culture supernatants
were collected 72 h later and filter sterilized. The viral titers were quantitated
either by a reverse transcriptase assay (32) or through p24 enzyme immunoassay
(Beckman-Coulter). Prior to infection, U937 cells were serum starved for 90 min,
and 2  106 cells were infected with about 100,000 to 200,000 reverse transcrip-
tase counts. After 2 h of infection, complete medium was added. Cells were
collected at various times postinfection and used for immunoprecipitation or
flow cytometry.
Cloning and expression of vpu. The vpu gene was PCR amplified with Pfu
polymerase (Stratagene, La Jolla, CA), using a 3.5-kb fragment encompassing
the vpr-to-env region, previously amplified and cloned from a primary isolate of
HIV-1 subtype C, as a template. The PCR primers used were as follows (with
restriction sites shown in italics): Vpu-R5-F, GGATCCATGTTAAATTTAGA
TTATAAATTAGGAGTAGG; and Vpu-R5-R, GAATTCATTACAAATCATT
AACATCCAAAAGCC. The amplified fragment designated R5 vpu was cloned
into plasmid pGEM-T Easy (Promega, Madison, WI) and sequenced in both
directions. The gene fragment corresponding to the TM domain of Vpu was
assembled from the synthetic oligonucleotides R5-TM-F (CATGGAGATGTT
AAATTTAGATTATAAATTAGGAGTAGGAGCATTGATAGTAGCACTA
ATCATAGCAATAGTCGTGTGGACCATAGTATATATAGAATAGG) and
R5-TM-R (AATTCCTATTCTATATATACTATGGTCCACACGACTATTG
CTATGATTAGTGCTACTATCAATGCTCCTACTCCTAATTTATAATCTA
AAT0054TAACATCTC). The gene fragment corresponding to the cytoplasmic
domain of Vpu was PCR amplified using primers R5-Cyto-F (CCATGGAGTA
TAGGAAATTGGTACAAC) and Vpu-R5-R.
To express a maltose-binding protein–Vpu (MBP-Vpu) fusion protein, the vpu
gene was cloned as a BamHI-EcoRI fragment into the pMal-c2 vector (New
England Biolabs, Beverly, MA). Following induction of a freshly diluted over-
night culture of transformed Escherichia coli BL21(DE3) cells with 1 mM IPTG
(isopropyl--D-thiogalactopyranoside) for 4 h at 37°C, the cells were harvested,
resuspended in phosphate-buffered saline (PBS) containing 0.1% Triton X-100,
10 g/ml lysozyme, and 1 mM phenylmethylsulfonyl fluoride, and subjected to
five cycles each of freeze-thaw and sonication. The sample was centrifuged at
12,000 rpm at 4°C in a microcentrifuge (Biofuge 17RS; Heraeus, Germany). To
the clarified lysate, amylose resin (New England Biolabs, Beverly, MA) was
added, and the MBP-Vpu protein was allowed to bind for 2 h at 4°C. The resin
was washed with 10 volumes of wash buffer (20 mM Tris-HCl, pH 7.4, 0.2 M
NaCl, 10 mM -mercaptoethanol, and 1 mM EDTA) to remove nonspecifically
bound proteins. The bound proteins were eluted with wash buffer containing 50
mM maltose. Similarly purified MBP was used as a control.
The full-length Vpu protein and its cytoplasmic or transmembrane mutant
proteins were also synthesized in vitro and labeled with [35S]methionine-cysteine.
For this purpose, a coupled in vitro transcription-translation system (TNT; Pro-
mega, Madison, WI) was used according to the manufacturer’s guidelines. The in
vitro system was programmed with pGBKT7 plasmids carrying the required gene
fragments, whose details are given in the following section.
Yeast two-hybrid library screening and assays. The GAL4-based two-hybrid
system contained the DNA binding domain (BD) vector pGBKT7 and the
activation domain (AD) vector pGADT7. The R5 vpu gene was cloned into the
pGBKT7 vector as an EcoRI-BamHI fragment. The nucleotide sequences cor-
responding to the TM and cytoplasmic domains of the Vpu proteins were sim-
ilarly cloned into the two-hybrid vectors as NcoI-BamHI fragments. Expression
of the relevant fusion proteins from each of the Vpu two-hybrid constructs was
tested in a T7 polymerase-based in vitro coupled transcription-translation system
(Promega, Madison, WI), followed by immunoprecipitation with anti-Vpu anti-
bodies. A commercial human leukocyte-specific yeast two-hybrid cDNA library
(Matchmaker; Clontech, Germany) derived from mRNAs isolated from healthy
peripheral blood leukocytes pooled from 550 Caucasians was used for screening.
The library, containing 2  106 independent clones, was amplified to 3 redun-
dancy and titrated as suggested by the supplier. The plasmid DNA pool was
isolated by CsCl density gradient centrifugation. For the screen, plasmids pGBKT7-
vpu (BD-Vpu) and pAct-leukocyte cDNA (AD) were cotransformed into the
Saccharomyces cerevisiae strain AH109 (MATa trp1-901 his3 leu2-3,112 ura3-52
ade2 gal4 gal80 URA3::GAL-lacZ LYS2::GAL-HIS3), containing the HIS3 and
lacZ reporter genes under the control of GAL4-binding sites. The host strain,
containing plasmids pAS2-SNF1 and pACT2-SNF4, served as the positive con-
trol (19). Various negative controls that included single or dual transformants
were also run in the same assay. AH109 yeast cells were transformed using
lithium acetate and plated on synthetic dextrose in the absence of leucine,
tryptophan, and histidine (SD/LTH) to grow cotransformants containing Vpu
interactors. The clones that grew were replica plated on SD/LTH plates con-
taining 20 mM 3-amino-1,2,3-triazole (SD/LTH3AT) to select strong interac-
tors. -Galactosidase filter lift and liquid assays were carried out as described
earlier (24). From individual positive yeast clones on SD/LTH3AT plates, the
plasmid DNAs were isolated and used to transform E. coli DH5, selected on
LB-ampicillin plates to eliminate cells containing a plasmid(s) other than
pACT2. The plasmid DNAs so obtained were purified, digested with EcoRI and
XhoI, and analyzed in agarose gels. The inserts from these positive clones were
sequenced, and the sequences obtained were analyzed by BLAST searches.
A direct yeast two-hybrid assay was carried out using pGBKT7-vpu and pACT-
CD74 to confirm the interaction, essentially as described earlier (24). To identify
the CD74-interacting domain of Vpu, the assay was carried out using pACT-
CD74 and either pGBKT7-vpu(TM) or pGBKT7-vpu(cyto). AH109 yeast cells
were transformed using the lithium acetate procedure and plated on SD/LTH
plates to test protein interactions. Various negative controls that included single
or dual transformants were run in the same assay, with the host strain containing
plasmids pAS2-SNF1 and pACT2-SNF4 used as a positive control. The interac-
tion specificity was tested by replica plating on SD/LTH3AT plates and
through filter lift and liquid -galactosidase assays.
Synthesis of CD74 peptide and binding assays. The 30-aa cytoplasmic domain
of CD74 was synthesized in vitro using solid-phase 9-fluorenylmethoxy carbonyl
chemistry. The final synthesized peptide was cleaved from the resin with 94.5%
trifluoroacetic acid–1.25% EDTA for 2 h at room temperature, with gentle
shaking. The cleavage mixture with resin was filtered and the peptide precipi-
tated with cold ether. The peptide was dissolved in 5% acetic acid and lyophilized
for 16 h. The size and purity of the synthesized peptide were confirmed by
sodium dodecyl sulfate (SDS)-15% polyacrylamide gel electrophoresis and by
mass spectrometry. The peptide sequence was MHRRRSRSCREDQKPVMD
DQRDLISNNEQL.
For the binding assay, 200 ng of the CD74 cytoplasmic peptide, a nonspecific
adrenocorticotropin (ACTH) peptide, or the MBP-Vpu protein was used to coat
the wells of an enzyme-linked immunosorbent assay (ELISA) plate for 12 h at
4°C, and the plate was then blocked for 2 h at room temperature with 5% nonfat
milk in Tris-buffered saline containing 0.1% Tween 20 (TBST). The reticulocyte
reaction mixtures for 35S-labeled full-length, cytoplasmic, and transmembrane
Vpu proteins were added and incubated for 12 h at 4°C. A blank 35S reaction
mixture was used as a negative control. After three washes with TBST, the
retained 35S-labeled proteins were eluted in 100 l of TBS containing 1% SDS
and quantitated by scintillation counting. MBP-Vpu-coated wells were used as a
positive control. For another binding assay, an ELISA plate similarly coated with
CD74 and ACTH peptides was used to evaluate the binding of purified MBP-
Vpu or MBP (as a control). The purified proteins were diluted in TBST con-
taining 5% nonfat milk, and 400 ng of each protein was incubated in the well for
2 h at room temperature. After one wash, diluted (1:1,000) rabbit anti-MBP
antibodies in TBST containing 5% bovine serum albumin (BSA) were added and
incubated for 2 h at room temperature. This was followed by three washes with
TBST and incubation for 90 min at room temperature with diluted (1:2,000)
horseradish peroxidase-linked anti-rabbit immunoglobulin G in TBST contain-
ing 5% nonfat milk. Following three washes with TBST, the color was developed
with diaminobenzidine, and the optical density at 490 nm was measured.
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Immunoprecipitation and Western blotting. Human monocytic U937 cells
were infected with HIV-1 NL4-3 and NL4-3U35. Cells were collected at various
times postinfection and washed with PBS, and 4  106 cells were lysed using
450 l of radioimmunoprecipitation assay buffer lacking SDS. After incubation
on ice for 45 min, the lysates were clarified at 12,000 rpm for 10 min and the
supernatants incubated on ice for 1 h with 2.5 g of either mouse anti-human
CD74 (Serotech, Oxford, United Kingdom) or mouse anti-human epidermal
growth factor receptor (EGFR) (Santa Cruz Biotechnology, Santa Cruz, CA). To
this mixture, 50 l of a 50% suspension of radioimmunoprecipitation assay
buffer-washed protein A-Sepharose beads was added, and the mixture was in-
cubated with constant shaking at 4°C for 90 min. The beads were washed five
times with 0.5 ml of the lysis buffer, resuspended in 30 l of SDS-polyacrylamide
gel electrophoresis loading buffer, heated at 100°C for 5 min, and centrifuged,
and the supernatants were loaded on an SDS-12% polyacrylamide gel. For
Western blotting, proteins separated by SDS-polyacrylamide gel electrophoresis
were transferred to a nitrocellulose membrane (Hybond ECL). After being
blocked with TBS containing 10% BLOTTO (Bio-Rad) for 12 h at 4°C, the
membrane was washed with TBST and incubated for 2 h at room temperature
with a rabbit polyclonal anti-Vpu antibody diluted 1:1,000 in TBST containing
5% BSA. The blot was washed thrice for 10 min each with TBST and then
incubated for 90 min at room temperature with horseradish peroxidase-linked
anti-rabbit immunoglobulin G diluted 1:2,000 in TBST containing 5% BLOTTO.
The blot was again washed as described above, and chemiluminescence detection
of proteins was carried out using a Western blot detection system (Santa Cruz
Biotechnology, Santa Cruz, CA) according to the supplier’s guidelines.
Flow cytometry. Infected U937 cells were collected at the indicated times
postinfection, washed with PBS, and costained for either total or surface MHC
II together with p24 to score HIV-infected cells. The L243 monoclonal antibody
recognizes mature MHC II, while anti-CD74 measures levels of immature MHC
II as well as free CD74. The U937 cells were washed twice with PBS and then
fixed with 100 l of fixative (Dako IntraStain kit) for 15 min at room tempera-
ture. To this mixture, 100 l of L243 culture supernatant or 5 g of anti-CD74
was added, and the mixture was incubated at room temperature for 15 min. The
cells were washed in PBS and stained with 1 g (in 100 l) of Alexa 594-
conjugated anti-mouse (Molecular Probes) for 15 min at room temperature.
Following this step, the cells were permeabilized with 100 l of permeabilization
solution (Dako IntraStain kit) for 15 min and stained with 2 l fluorescein
isothiocyanate-conjugated anti-p24 (Beckman-Coulter). For total MHC II intra-
cellular staining, the cells were fixed, permeabilized, and stained with L243 as
described above. Following two washes in PBS containing 1% BSA, the same
permeabilized cells were stained for p24. The cells were then washed twice in
PBS containing 1% BSA and resuspended in 500 l of the same for acquisition.
For total CD74 and p24, fixed and permeabilized cells were simultaneously
costained with 2 l each of phycoerythrin-conjugated anti-CD74 (Santa Cruz)
and fluorescein isothiocyanate-conjugated anti-p24. The stained cells were ac-
quired using a Cyan-ADP flow cytometer (Dako, Denmark), and data were
analyzed using Summit software, version 4.3. U937 cells transfected with expres-
sion vectors for a Vpu-enhanced green fluorescent protein (Vpu-EGFP) fusion
protein or EGFP as a control were similarly stained for surface or total levels of
MHC II or CD74.
Antigen presentation assay. The Ova-myc plasmid has been described previ-
ously (8). Murine BMC-2 cells were transfected with the appropriate plasmids,
and 12 h later, the dead cells were removed by flotation on Ficoll-Hypaque. The
live cells obtained (3  106 cells/ml) were then used to stimulate OT-II T-cell-
receptor-transgenic mouse splenic CD4 T cells (3  106 cells/ml) for 24 h as
described earlier (8). Activation-induced proliferation of CD4 T cells was
measured by [3H]thymidine incorporation. As controls for cell death during the
assay, the transfected BMC-2 cells were stained with propidium iodide 12 h and
24 h into the stimulation assay, and apoptotic cells were quantitated by flow
cytometry.
RESULTS
The Vpu protein interacts with CD74. To identify novel
cellular proteins that would interact with it, the HIV-1 Vpu
protein was used in a yeast two-hybrid screen of a human
leukocyte cDNA library. As described in Materials and Meth-
ods, the screen was made stringent by selecting only strongly
interacting proteins by growing cotransformants on SD/LTH
plates containing 20 mM 3-AT and then assaying for reporter
-galactosidase activity. From an activation domain library of
2  106 clones, about 1,000 cotransformants with BD-Vpu
grew on SD/LTH plates, and this number was reduced to 350
on SD/LTH3AT plates. Of these, 80 clones showed reporter
-galactosidase activity. Plasmid DNAs isolated from these
yeast clones were amplified in E. coli, transformed back into S.
cerevisiae AH109 cells, grown on yeast extract-peptone-dex-
trose plates, and replica plated on SD/LH plates. Thirty
clones did not grow on SD/LH plates and represented the
true interactors. Plasmid DNAs isolated from these were re-
striction digested, and those with unique inserts were se-
quenced.
Through this process, the genes for four unique proteins,
hitherto not reported to bind Vpu, were identified. One of
these was CD74, a type II integral membrane protein. It is also
known as Ii, the invariant chain that binds to MHC II mole-
cules before antigen loading in the endolysosomal compart-
ment. The CD74 protein has an N-terminal cytoplasmic do-
main of 30 aa followed by a 26-aa TM domain and a 160-aa
domain that either projects into the lumen or is extracellular,
depending upon its subcellular location. The association of
CD74 and MHC II occurs inside the ER, but the complex is
also found on the cell surface, possibly en route to the endoly-
sosomal compartment, where CD74 is degraded and MHC II
is loaded with exogenously acquired peptides. Since Vpu is also
localized to the ER-Golgi region, it is likely that the CD74-Vpu
interaction takes place in this compartment.
Vpu and CD74 cytoplasmic domains are required for their
interaction. A direct yeast two-hybrid assay was carried out to
confirm the CD74-Vpu interaction. As shown in Fig. 1A, a
strong interaction was observed between the two proteins. Be-
sides growing on SD/LTH plates containing 20 mM 3-AT
(Fig. 1A, panel 6), the AD-CD74/BD-Vpu cotransformants
showed -galactosidase reporter activity in a filter assay (Fig.
1A, panel 7) as well as in a semiquantitative liquid -galacto-
sidase chromogenic assay (Fig. 1B). To identify the CD74-
interacting domain of Vpu, regions of the vpu gene corre-
sponding to the TM and cytoplasmic domains were cloned into
plasmid pGBKT7. As described in Materials and Methods, the
yeast two-hybrid assay was repeated using pACT-CD74 and
either pGBKT7-vpu(TM) or pGBKT7-vpu(cyto). The results
summarized in Fig. 1B show that the Vpu cytoplasmic domain,
but not its TM domain, was responsible for the interaction with
CD74.
Due to the topology of the two proteins, we reasoned that
the cytoplasmic domain of Vpu is likely to bind the N-terminal
cytoplasmic domain of CD74. To test this, a 30-aa peptide
corresponding to the entire cytoplasmic domain of CD74 (aa 1
to 30) was chemically synthesized. This peptide was used as the
coating antigen on an ELISA plate to test Vpu binding. A
nonspecific peptide was used as the coating control. In the first
assay, [35S]methionine-cysteine-labeled Vpu proteins were syn-
thesized in vitro in a coupled transcription-translation system
and used to bind to peptide-coated wells. As shown in Fig. 2A,
significantly higher 35S counts were retained in CD74 peptide-
coated wells that received either full-length Vpu or its cyto-
plasmic portion, but not its TM domain. On the other hand,
only background counts were retained in wells coated with the
nonspecific ACTH peptide. Similarly, the MBP-Vpu fusion
protein, but not control MBP, was preferentially retained in
CD74 peptide-coated wells but not in wells coated with the
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ACTH peptide (Fig. 2B). These in vitro assays support the
yeast two-hybrid results of Vpu-CD74 interaction and show
that the cytoplasmic regions of the two proteins are required
for their interaction.
Vpu binds to CD74 in HIV-1-infected cells. To detect the
interaction of Vpu and CD74 in HIV-1-infected cells, the hu-
man monocytic cell line U937 was used. U937 cells constitu-
tively express endogenous CD74 as well as the MHC II  and
 chains. The U937 cells were infected with HIV-1 NL4-3 or
the Vpu-defective mutant NL4-3U35. Cells were collected at
various times postinfection, and the lysates were immunopre-
cipitated with anti-CD74 antibodies and then Western blotted
with anti-Vpu antibodies. As shown in Fig. 3, anti-CD74 anti-
bodies efficiently precipitated Vpu from NL4-3-infected cells,
while no precipitation was seen from NL4-3U35-infected cell
lysates. It is known that Vpu is expressed late in viral infection,
starting at about 40 h postinfection. While at early times
postinfection (24 h) no Vpu could be immunoprecipitated
FIG. 1. Yeast two-hybrid analysis of Vpu-CD74 interaction. (A) Representative plates showing interactions of Vpu and CD74. Panel 1 shows
the template for panels 2 to 7, which in turn show transformants streaked on each section of the following plates: 2, yeast extract-peptone-dextrose;
3, SDLeu; 4, SDTrp; 5, SDLeuTrp; and 6, SDLeuTrpHis. Panel 7 shows a -galactosidase filter assay. Growth is seen as light streaks
on a dark background (panels 2 to 6). The -galactosidase signal (panel 7) is seen as dark streaks on a white background. (B) Complete results
for the entire screen, using CD74 and full-length, TM domain, and cytoplasmic domain (cyto) Vpu fusions to the Gal4 protein AD or BD. Growth
() or no growth () of transformants on various media is shown. LTH3AT represents growth on SDLeuTrpHis plates containing 20 mM
3-AT. The liquid -galactosidase assay values represent averages of two independent measurements. Various negative and positive controls are
also shown.
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from NL4-3-infected cells, it could be precipitated efficiently
later in infection. Direct Western blotting of infected cell ly-
sates showed a similar expression pattern for Vpu (Fig. 3). To
confirm that Vpu does not bind nonspecifically to cellular
proteins, we used an isotype-matched anti-EGFR antibody for
immunoprecipitation, followed by Western blotting for Vpu.
No Vpu was immunoprecipitated under conditions that
brought down large amounts of EGFR (Fig. 3). Together,
these results confirm a direct interaction between the HIV-1
Vpu protein and host cell CD74 in virus-infected cells and
support the in vitro results shown above.
Vpu modulates MHC II levels in HIV-infected and trans-
fected cells. Since CD74 is critical for MHC II presentation, we
tested the effects of Vpu on MHC II levels in infected and
transfected cells. Human monocytic U937 cells were activated
with 10 ng/ml phorbol myristic acid for 24 h to induce MHC II
expression and then infected with either HIV-1 NL4-3 or the
Vpu-defective NL4-3U35 virus. The infected cells were col-
lected at 24 and 44 h postinfection, stained for surface and
total MHC II, using either the L243 antibody, which recognizes
mature MHC II, or the MCA2364 antibody, which recognizes
Ii (CD74) present on immature MHC II, and analyzed by flow
cytometry by gating on the p24-positive population. The anti-
CD74 antibody is directed to the luminal region of the CD74
FIG. 2. Vpu binding to CD74 cytoplasmic domain peptide. (A) In vitro-synthesized 35S-labeled Vpu proteins retained in wells coated with
either a CD74 cytoplasmic domain peptide or a nonspecific peptide (ACTH). The results shown are averages of triplicate measurements.
Autoradiograms on the right show crude in vitro translation mixtures run together with molecular size markers. (B) Purified MBP-Vpu or MBP
control retained in wells coated with either a CD74 cytoplasmic domain peptide or the nonspecific ACTH peptide. The results shown are averages
of triplicate measurements. The Coomassie blue-stained SDS gel on the right shows purified proteins.
FIG. 3. Coimmunoprecipitation of Vpu and CD74 from HIV-in-
fected cells. U937 cells were infected with HIV-1 NL4-3 (Vpu) or
NL4-3U35 (Vpu), and cell lysates were prepared at the indicated
times postinfection. The lysates were then immunoprecipitated (IP)
with anti-CD74 followed by Western blotting (WB) with anti-Vpu. The
immunoprecipitated Vpu proteins are shown. Alternatively, infected
cell lysates were directly Western blotted with anti-Vpu antibodies.
As nonspecific controls, the same lysates were also immunoprecipi-
tated with an isotype-matched anti-EGFR rabbit polyclonal anti-
body followed by Western blotting with either anti-Vpu or anti-
EGFR antibody.
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protein and would also stain CD74 protein present on the cell
surface or in subcellular compartments. The results are shown
in Fig. 4. At 24 h postinfection, a slight decrease in mature
MHC II was observed on the surfaces of cells infected with
NL4-3 compared to that on cells infected with NL4-3U35; this
was also the case with total MHC II (Fig. 4A). In earlier
experiments wherein cells were not costained for p24, the sur-
face MHC II decrease at this early time point was found to be
independent of Vpu (not shown). At 44 h postinfection, a
larger decrease in mature MHC II staining was observed on
the surfaces of NL4-3-infected cells than on those of cells
infected with the Vpu-defective NL4-3U35 virus (Fig. 4A). A
similar pattern was observed when mature MHC II levels were
estimated for permeabilized U937 cells stained with the L243
antibody. No significant decrease in surface or total levels of
immature MHC II (or CD74) was observed in infected cells at
24 or 44 h postinfection (Fig. 4B). Together, these results
suggest that Vpu down regulates the surface as well as total
levels of mature MHC II in HIV-infected cells. This effect was
observed late but not early in infection, again suggesting the
involvement of Vpu, which is expressed late during the viral
life cycle.
The effects of ectopic expression of Vpu on MHC II were
also analyzed. Activated human U937 macrophages or murine
BMC-2 macrophages were transfected to express either a Vpu-
EGFP fusion protein or EGFP as a control. Cells were stained
for surface and total levels of mature MHC II with L243
antibody and quantitated by flow cytometry. Among cells gated
for EGFP expression, Vpu reduced mature MHC II on the
surfaces of transfected cells (P 	 0.02), but the apparent dif-
ferences in immature surface MHC II (or CD74) were not
statistically significant (P 	 0.09) (Fig. 5). In BMC-2 cells, the
effects were more pronounced, with Vpu showing larger down
modulation of both surface and total MHC II levels. The levels
of immature MHC II (or CD74) were not statistically different
between Vpu-expressing and control cells (not shown).
Vpu attenuates T-cell activation. Down regulation of mature
MHC II is likely to result in reduced antigen presentation to T
cells. This was tested using a mouse cell system. The mouse
macrophage cell line BMC-2 was cotransfected with plasmids
that express a Vpu-EGFP fusion protein and myc-tagged
ovalbumin (Ova-myc). As controls, BMC-2 cells were also
transfected with individual expression plasmids and a cotrans-
fection control comprising of Ova-myc and EGFP expression
plasmids. The expression of Ova-myc and Vpu-EGFP in
BMC-2 cells is shown in Fig. 6A and B. The cotransfected
BMC-2 cells were then purified to remove dead cells, and the
live cells were used as stimulator antigen-presenting cells
FIG. 4. Vpu alters MHC II expression in virus-infected APCs. Activated U937 cells were infected with either HIV-1 NL4-3 or NL4-3U35.
(A) At 24 h or 44 h postinfection, cells were fixed and labeled with anti-p24 and the L243 antibody (for mature MHC II), either without
permeabilization for surface levels or after permeabilization for total levels. (B) The cells were similarly stained with anti-p24 and anti-CD74 (for
immature MHC II) antibodies. Labeled cells were quantitated by flow cytometry. Single-parameter plots are shown for cells gated on p24
expression. The inset data show mean fluorescence intensities (
 standard deviations) calculated over two separate experiments, each with
duplicate samples.
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(APCs) for Ova-specific MHC II-restricted CD4 T cells from
the OT-II transgenic mouse. Stimulator APC-directed T-cell
activation was measured by [3H]thymidine incorporation. As
shown in Fig. 6C, BMC-2 cells coexpressing Ova-myc and
Vpu-EGFP attenuated activation of the CD4 T cells com-
pared to BMC-2 cells that coexpressed Ova-myc and EGFP or
expressed only the Ova-myc protein. Since Vpu is known to be
proapoptotic, it was important to also demonstrate that atten-
uated T-cell activation by Vpu-expressing cells was not due to
apoptotic death of these APCs. We therefore stained cells
coexpressing Ova-myc plus EGFP and Ova-myc plus Vpu-
EGFP with propidium iodide and quantitated the apoptotic
cells at different times during the activation assay. Although
Vpu-expressing cells showed about twice as much apoptosis as
control cells, these were still a very small fraction of the total
cells (Fig. 6D) and would not account for the differences in
T-cell stimulation observed in Fig. 6C. Thus, the reduced sur-
face expression of mature MHC II in Vpu-expressing cells is
also functionally relevant in down modulating T-cell activation.
DISCUSSION
Primate lentiviruses carry a number of accessory proteins
not commonly found in other retroviruses. While these pro-
teins are not required for viral replication in all cells in vitro,
they modulate replication, virus spread, and survival of the
host cell in the background of some cell types. However, in vivo
studies have clearly demonstrated a role for these proteins in
viral pathogenesis, with their inactivation leading to dramatic
attenuation of disease progression and severity (18). These
proteins appear to work as multifunctional adaptors that re-
cruit cellular proteins as a means to modulate host cellular
processes. Such modulation translates into optimization of vi-
ral replication through wide-ranging effects on infectivity, gene
expression, and production of new virions.
The primary role of Vpu is to increase the synthesis and
release of new virions (4). This is based on two independent
activities of Vpu. The first is its ability to mediate interaction of
CD4 with the TrCP-Skp1-Cul1 complex at the ER, leading to
ubiquitination, retrotranslocation, and proteasomal degrada-
tion of the CD4 protein (53). This prevents formation of a
CD4-gp160 complex in the ER, allowing the HIV envelope
glycoprotein to transit to the plasma membrane. Vpu is also a
cation-selective ion channel (13), and its interaction with the
TASK-1 K channel was shown to suppress the latter activity
and promote the release of new virions (22). The strongest
evidence for a role of Vpu in HIV-1 pathogenesis comes from
studies of monkeys infected with SHIV. Deletion of the vpu
gene in this background led to decreased viral loads in animals
infected with SHIV (30). Furthermore, an intact vpu gene was
found to be important for the CD4 T-cell loss during infec-
tion with pathogenic SHIV (46). Current models of Vpu action
suggest that by increasing viral loads, it contributes to virus
spread, which in turn results in increased rates of mutation in
the env and nef genes (33, 45). Accumulating mutations in env
would contribute positively to the development of neutraliza-
tion escape variants that drive disease progression and virus
transmission to a naı¨ve host (35).
While searching for novel Vpu-interacting cellular proteins
FIG. 5. Effect of transfected Vpu on MHC II expression. Activated U937 or BMC-2 cells were transfected to express either Vpu-EGFP
or EGFP, and at 24 h posttransfection, cells were stained for surface or total levels of mature MHC II as in Fig. 4. Single-parameter plots
are shown for cells gated on EGFP expression. The inset data show mean fluorescence intensities (
 standard deviations) calculated over
three separate experiments, each with duplicate samples. The P values were calculated by Student’s t test, and values of 0.05 were
considered not significant (ns).
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in a yeast two-hybrid screen, we found the MHC II Ii or CD74
protein to bind Vpu. This protein is a type II transmembrane
protein that binds the MHC II  and  chains in the ER (3).
This complex moves through the Golgi complex to the MHC II
compartment, where peptide loading occurs by displacement
of the class II-associated Ii peptide (CLIP) domain of CD74
before the mature MHC II-peptide complex is presented on
the cell surface (39). The displaced CLIP domain is further
cleaved by I-CLIP proteases to release a 42-aa cytoplasmic
peptide that translocates to the nucleus to modulate transcrip-
tion of critical survival genes (27). The CD74 protein is also
expressed as a trimer on the cell surface and is responsible for
mediating signaling initiated by the macrophage migration in-
hibitory factor (28). Thus, CD74 or Ii is involved in multiple
cellular functions that involve MHC II presentation as well as
signal transduction. Here we explored the effects of HIV-1
Vpu on MHC II presentation.
In an earlier report, using the HIV-2 Vpx protein as a bait,
Pancio et al. (38) similarly pulled out CD74 from a yeast
two-hybrid screen. Their results showed that a C-terminal
83-aa region of CD74 interacted with a 20-aa amphipathic
helix in the Vpx protein. We observed that the extreme C-
FIG. 6. Vpu attenuates T-cell activation by APCs. (A) Two-parameter plots showing frequencies of Ova-myc expression in untransfected
BMC-2 cells () or BMC-2 cells transfected to express Ova-myc plus EGFP or Ova-myc plus Vpu-EGFP, as indicated. The gates for OVA-myc-P
cells are also shown. (B) Histograms show staining levels for Vpu-EGFP in Ova-myc-P cells from Ova-myc- plus EGFP-transfected (dotted curve)
or Ova-myc- plus Vpu-EGFP-transfected (black shaded curve) cultures. The gray shaded curve is the isotype control curve. (C) Ova-specific MHC
II-restricted responses of primary T cells from OT-II transgenic mice to variously transfected BMC-2 cells, as indicated. All data are means 

standard errors for triplicate cultures. T-cell activation was measured as [3H]thymidine incorporation into cellular DNA. The Western blot (WB)
shows the expression of Ova in transfected cells stained with anti-myc antibodies. (D) Histograms showing propidium iodide staining of BMC-2
cells transfected with either Ova-myc plus EGFP or Ova-myc plus Vpu-EGFP at different times into the stimulation assay. Cells at 0 h correspond
to those immediately after Ficoll-Hypaque purification or at 12 h posttransfection.
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terminal 30 aa that comprise the cytoplasmic domain of CD74
interacted with the cytoplasmic domain of Vpu (Fig. 1 and 2).
This region of the Vpu protein is made up of two helices, of
which helix 1 is amphipathic (6) and, by analogy, is the likely
interaction site for CD74. Taken together, our results and
those of Pancio et al. (38) suggest that binding CD74 is likely
to be important for the HIV/SIV group of lentiviruses. While
Vpu carries out this function for HIV-1, the Vpx protein fulfils
this role for HIV-2 and SIV.
What might be the functional significance of binding CD74?
Since it is the class II invariant chain, this interaction is likely
to affect MHC II presentation during HIV infection. In human
monocytic U937 cells infected with wild-type and Vpu-defec-
tive HIV-1, we observed a slight decrease in surface MHC II
presentation early in infection. This effect was Vpu indepen-
dent and may have been due to Nef, an accessory protein of
HIV that is expressed early in infection. Besides promoting the
endocytosis of immunologically important cell surface mole-
cules, such as MHC I molecules (43) and the B7 family pro-
teins (8, 9), Nef also down regulates surface MHC II molecules
(49), albeit with slow kinetics and a half-life of about 24 h
(Chaudhry et al., unpublished data). At later times following
infection, Vpu-dependent down modulation of surface as well
as total MHC II was observed in infected U937 cells. This also
correlated with the timing of Vpu expression and its interac-
tion with CD74 following infection. Ectopic expression of Vpu
in transiently transfected U937 or BMC-2 cells also showed
surface down modulation of mature MHC II, in agreement
with the infection results.
Viruses have evolved various strategies to evade the host
immune response. One critical element in the adaptive im-
mune response is the ability of CD4 T cells to provide help
for differentiation of B cells and CD8 T cells. This, in turn,
depends upon the ability of CD4 T cells to recognize exog-
enously acquired antigens presented efficiently on the surfaces
of APCs in association with MHC II  and  chains. Our
results show that HIV-1 Vpu reduces the cell surface levels of
mature MHC II molecules in infected APCs and that this
interferes with the ability of Vpu-transfected APCs to effi-
ciently present Ova peptides to Ova-specific MHC II-restricted
T cells. However, during HIV infection, only a small number of
APCs are infected; the remaining, uninfected APCs would
continue to express normal levels of cell surface MHC II and
to provide T-cell help. While Vpu can down modulate the
antiviral immune response and contribute to pathogenesis and
viral persistence, this is likely to be a minor pathway. Never-
theless, these results show the rich diversity and functional
redundancy of HIV in its immune evasion strategies.
There are several examples of viral down modulation of the
MHC presentation pathway (39). For example, the adenovirus
E3-19K protein binds and retains the MHC I heavy chain in
the ER (7), while herpes simplex virus ICP47 inhibits the ER
peptide transporters TAP1 and -2, thus blocking peptide access
to the ER lumen (15, 21). Cytomegaloviruses (CMVs) carry
multiple proteins that interfere with the MHC I pathway. HIV
also uses its Nef and Vpu proteins to interfere with the MHC
I pathway. While Nef, an early protein, promotes endocytosis
of MHC I from the surfaces of APCs (43), the late Vpu protein
interferes with biosynthesis of the MHC I heavy chain (25). In
studies on viral down regulation of the MHC II pathway, CMV
was shown to interfere with expression of the MHC II heavy
chain through repression of class II transactivator expression
(20, 29, 34). Direct effects of CMV on global protein secretion
were also shown to inhibit MHC II trafficking to the cell sur-
face. Herpes simplex virus infection strongly reduces invariant
chain (Ii; CD74) expression (37), and the viral glycoprotein B
competes with Ii for binding to HLA-DR (37, 44). The Nef
protein of HIV also impairs MHC II presentation by reducing
the surface levels of mature MHC II while increasing the levels
of functionally incompetent immature MHC II (49). We ob-
served similar effects of the HIV-1 Vpu protein.
We report here a role for the HIV-1 Vpu protein in down
modulating MHC II presentation on APCs. We propose that
by binding the class II invariant chain (CD74), Vpu prevents
maturation of MHC II, something monitored in our experi-
ments with the L243 monoclonal antibody. This would be a
novel strategy for interfering with MHC II presentation, unlike
the effects of Nef, which are likely due to the modification of
intracellular MHC II trafficking (49). An instance of direct
binding of CD74 was demonstrated for the HIV-2 Vpx protein
(38), but the functional relevance of that binding for MHC II
presentation was not studied. The results presented here add
to the growing list of strategies used by HIV to evade the host
immune response towards the goal of establishing a successful
persistent infection.
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